[Lung cancer in HIV-infected patients]

Bull Cancer. 2018 Jan;105(1):111-119. doi: 10.1016/j.bulcan.2017.11.002. Epub 2017 Dec 22.
[Article in French]

Abstract

Until 1996, AIDS was the leading cause of deaths from HIV infection. In 2010, because of introduction of powerful antiretroviral therapies, AIDS represented less than 25% of deaths. Cancer has become the leading cause of death in this population, and, because of smoking and immunosuppression, lung cancer risk is more important than in general population. Furthermore, treatment is more difficult, due to potential interactions between antiretroviral and anticancer therapies, to comorbidities and to tumor aggressiveness. Research will focus on molecular biology, immunotherapies and lung cancer screening in order to improve survival of HIV patients with lung cancer. For all these reasons, HIV patients must be included in clinical trials.

Keywords: Antiretroviral and chemotherapies interactions; Cancer du poumon; Epidemiology; HIV infection; Infection par le VIH; Interactions entre les antirétroviraux et les chimiothérapies; Lung cancer; Épidémiologie.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Drug Interactions
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / mortality
  • HIV Long-Term Survivors
  • Humans
  • Immunocompromised Host
  • Immunotherapy
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / mortality
  • Risk Factors
  • Smoking

Substances

  • Anti-HIV Agents
  • Antineoplastic Agents